Movement Disorders (revue) - Exploration (Accueil)

Index « Keywords » - entrée « Dopamine Agents (adverse effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Dopamine Agents (administration & dosage) < Dopamine Agents (adverse effects) < Dopamine Agents (blood)  Facettes :

List of bibliographic references indexed by Dopamine Agents (adverse effects)

Number of relevant bibliographic references: 50.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000109 (2015) Eugene V. Mosharov [États-Unis] ; Anders Borgkvist ; David SulzerPresynaptic effects of levodopa and their possible role in dyskinesia.
000599 (2014) Alice Laudisio [Italie] ; Davide L. Vetrano ; Eleonora Meloni ; Diego Ricciardi ; Francesco Franceschi ; Anna Rita Bentivoglio ; Roberto Bernabei ; Giuseppe ZuccalàDopaminergic agents and nutritional status in Parkinson's disease.
000767 (2013) Erwan Bezard [France] ; Elisabetta Tronci ; Elsa Y. Pioli ; Qin Li ; Gregory Porras ; Anders Björklund ; Manolo CartaStudy of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
000861 (2013) Alex A. Macdonald [Canada] ; Oury Monchi ; Ken N. Seergobin ; Hooman Ganjavi ; Ruzbeh Tamjeedi ; Penny A. MacdonaldParkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
000933 (2013) Roser Pons [Grèce] ; Dimitris Syrengelas ; Sotiris Youroukos ; Irene Orfanou ; Arqirios Dinopoulos ; Bru Cormand ; Aida Ormazabal ; Angels Garzía-Cazorla ; Mercedes Serrano ; Rafael ArtuchLevodopa-induced dyskinesias in tyrosine hydroxylase deficiency.
000934 (2013) Erwan Bézard ; C Warren Olanow ; José A. ObesoLevodopa-induced dyskinesias in the absence of nigrostriatal degeneration.
000945 (2013) Pauline Belujon ; Anthony A. GraceL-DOPA treatment duration versus Parkinson's Disease progression: The dorsal-ventral divide
000A19 (2013) David E. Vaillancourt [États-Unis] ; Daniel Schonfeld [États-Unis] ; Youngbin Kwak [États-Unis] ; Nicolaas I. Bohnen [États-Unis] ; Rachael Seidler [États-Unis]Dopamine overdose hypothesis: Evidence and clinical implications
000B26 (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
001269 (2011) Evžen Růži Ka [République tchèque] ; Kate Ina Zárubová [République tchèque] ; John G. Nutt [États-Unis] ; Bastiaan R. Bloem [Pays-Bas]“Silly Walks” in Parkinson's disease: Unusual presentation of dopaminergic‐induced dyskinesias
001276 (2011) Angelo Antonini [Italie] ; Pablo Martinez-Martin [Espagne] ; Ray K. Chaudhuri [Royaume-Uni] ; Marcelo Merello [Argentine] ; Robert Hauser [États-Unis] ; Regina Katzenschlager [Autriche] ; Per Odin [Allemagne] ; Mark Stacy [États-Unis] ; Fabrizio Stocchi [Italie] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Anette Schrag [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Wearing‐off scales in Parkinson's disease: Critique and recommendations
001789 (2011) Maurizio Zibetti [Italie] ; Aristide Merola [Italie] ; Laura Rizzi [Italie] ; Valeria Ricchi [Italie] ; Serena Angrisano [Italie] ; Corrado Azzaro [Italie] ; Carlo Alberto Artusi [Italie] ; Nichy Arduino [Italie] ; Alice Marchisio [Italie] ; Michele Lanotte [Italie] ; Mario Rizzone [Italie] ; Leonardo Lopiano [Italie]Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease
001944 (2010) Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
001E45 (2010) Petra Schwingenschuh [Royaume-Uni, Autriche] ; Petra Katschnig [Royaume-Uni, Autriche] ; Ronald Saurugg [Autriche] ; Erwin Ott [Autriche] ; Kailash P. Bhatia [Royaume-Uni]Artistic profession: A potential risk factor for dopamine dysregulation syndrome in Parkinson's disease?
002007 (2009) Livia Brusa [Italie] ; Antonio Orlacchio [Italie] ; Vincenzo Moschella [Italie] ; Cesare Iani [Italie] ; Giorgio Bernardi [Italie] ; Nicola Biagio Mercuri [Italie]Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
002008 (2009) Jan-Philipp Bach [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Richard Dodel [Allemagne] ; Frank Jessen [Allemagne]Treatment of hypersexuality in Parkinson's disease with carbamazepine—A case report
002132 (2009) Hiroki Fujioka [Japon] ; Haruo Shintaku [Japon] ; Satoshi Kudo [Japon] ; Tsunekazu Yamano [Japon] ; Hiroki Fujioka [Japon]Plasma phenylalanine level in dopa‐responsive dystonia
002152 (2009) Olav B. Nielssen [Australie] ; Raymond J. Cook [Australie] ; Ron Joffe [Australie] ; Linton J. Meagher [Australie] ; Paul Silberstein [Australie]Paraphilia and other disturbed behavior associated with dopamimetic treatment for Parkinson's disease
002388 (2009) Gabriel Robert [France] ; Dominique Drapier [France] ; Marc Verin [France] ; Bruno Millet [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]Cognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology
002879 (2008) John G. Nutt [États-Unis] ; Steven A. Gunzler [États-Unis] ; Trish Kirchhoff [États-Unis] ; Penelope Hogarth [États-Unis] ; Jerry L. Weaver [États-Unis] ; Michael Krams [États-Unis] ; Brenda Jamerson [États-Unis] ; Frank S. Menniti [États-Unis] ; Jaren W. Landen [États-Unis]Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism
002E82 (2007) Astrid Thomas [Italie] ; Laura Bonanni [Italie] ; Angelo Antonini [Italie] ; Paolo Barone [Italie] ; Marco Onofrj [Italie]Dopa‐responsive pseudo‐orthostatic tremor in parkinsonism

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Dopamine Agents (adverse effects)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Dopamine Agents (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Dopamine Agents (adverse effects)
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024